
The company reported higher sales and a standalone profit for the first six months, while operating cash flow also turned positive.
Turk Ilac ve Serum Sanayi reported standalone net profit of TL101,746,058 for the six months ended June 30, 2026, compared with a net loss of TL754,155,600 a year earlier. The company’s financial statements were filed with KAP on Oct. 12.
Revenue reached TL2,917,503,375, up from TL1,866,942,375 in the same period of 2025. Gross profit increased to TL1,044,279,938 from TL521,279,161, while operating profit was TL791,719,073, compared with TL323,510,930.
Finance expenses totaled TL1,006,546,020. A net monetary position gain of TL350,255,856 was also reported, and profit before tax was TL196,461,372.
Cash from operating activities was TL105,290,801, versus an outflow of TL435,974,699 a year earlier. Investing activities used TL509,819,040, including TL956,575,254 in purchases of tangible and intangible assets and TL446,756,214 in proceeds from tangible-asset sales.
The statements are non-consolidated, so they cover the company on a standalone basis. The equity statement records a TL875,195,000 capital increase alongside an equal reduction in capital adjustment differences; these entries show a shift between reported equity lines, not a net change across those two amounts.
This article was produced with the help of AI technology. Source: Yahoo Finance